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Background: In contrast with breast cancers (BCs) in other parts of the world, most previous studies reported that
the majority of BCs in sub-Saharan Africa are estrogen-receptor (ER) negative. However, a recent study using the US
SEER database showed that the proportion of ER-negative BC is comparable between US-born blacks and West-African
born blacks but substantially lower in East African-born blacks, with over 74% of patients Ethiopians or Eritreans.
In this paper, we provide the first report on the proportion of ER-negative BC in Ethiopia, and the relation to
progesterone-receptor (PgR) status.
Methods: We analysed 352 female patients with ER results available out of 1208 consecutive female BC patients
treated at Addis Ababa-University Hospital, Ethiopia, from June 2005 through December 2010. The influences of
age, stage, and histology on the probability of ER-negative tumours were assessed by a log-linear regression model.
Results: Of the 352 patients, only 35% were ER-negative. The proportion of ER-negative tumours decreased with
advancing age at diagnosis and was not affected by histology or stage. For age, the proportion decreased by 6%
for each additional 5 years (stage-adjusted prevalence ratio PR = 0.94, 95% CI: 0.89–1.00). About 31% were ER- and
PgR-negative, and 69% were ER- and/or PgR-positive.
Conclusions: Contrary to most previous reports in other parts of sub-Saharan Africa, the majority of patients in
Ethiopia are ER-positive rather than ER-negative. These findings are in line with low proportions of ER-negative BCs
from East African immigrants within the SEER database, and they have clinical implications for management of BC
patients in Ethiopia and other parts of sub-Saharan Africa where ER-status is not ascertained as part of routine
management of the disease. Since the majority of patients showed ER-positive BC, Tamoxifen-therapy should be
given to all patients even with unknown ER status.
Keywords: Breast neoplasms, Africa, Ethiopia, Prognostic factorsBackground
Knowledge of the estrogen-receptor (ER) status of breast
cancer (BC) is essential in making the decision to treat
women with Tamoxifen. Population-based estimates of
the distribution of the receptor status of BCs can aid
treatment decisions, even among women in whom the
individual ER status has not been assessed. Often breast
tumours in the African setting are described as being* Correspondence: eva.kantelhardt@uk-halle.de
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article, unless otherwise stated.aggressive with negative ER status. Results from East
Africa showed 76% of the patients in Kenya and more
than two thirds of the patients in Tanzania and Uganda
were ER-negative [1-3]. The majority of studies from
West Africa showed more than half of the patients were
ER-negative: in Nigeria and Senegal, 76% [4]; in Ghana,
76% [5], 75% [6] and 53% [7] and in Mali, 61% [8]. One
study from Nigeria, one from Uganda, one from Ghana
and one large study from South Africa showed lower
proportions of ER-negative tumors (35%, 40%, 24% and
37%, respectively) [9-12] (Table 1).
The discrepancies in the proportion of ER-negative
tumours in Africa are thought to reflect the selectionntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Selection of published results of breast cancer hormone receptor-results (from PubMed terms “AFRICA” and
“BREAST CANCER” and “HORMONE RECEPTOR” or “ESTROGEN RECEPTOR” searched June 5, 2014)
Total (n) Year of specimen collection % of negative estrogen receptor status
East Africa
Kenia [1] 120 2001–2007 76
Tanzania [2] 60 1995–1997 67
Uganda [3] 65 1993–2002 65
West Africa
Nigeria/Senegal [4] 507 2004–2005 76
Ghana [5] 75 2007–2008 76
Ghana [6] 100 2006–2011 75
Ghana [10] 51 2007-2010 76
Mali [8] 114 2008–2011 61
Uganda [11] 45 2000-2004 60
Ghana [7] 68 2004–2009 53
Nigeria [9] 133 1996–2007 35
Southern Africa
South African black population [12] 957 2006–2012 37
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with laboratory procedures, including degradation of tissue
during storage. Also low sensitivity of ER-testing and false
negative cases can contribute. Possible regional differences
in populations may account for the heterogeneous results
involving these tumour biological characteristics but
this is questioned by studies showing large differences
in the ER-positive proportion within the same popula-
tion [10]. A recent publication by Jemal et al. showed
that U.S. immigrants from West Africa with BC had
high percentages of ER-negative disease (39.5%). U.S.
immigrants with BC from East Africa, mainly Ethiopia,
had ER-negative BC in only 25.3% similar to U.S.-born
whites with BC [13]. To investigate ER-negative propor-
tions of BC patients, we evaluated for the first time
patient and tumour characteristics of a case series of
female patients diagnosed with invasive BC from Addis
Ababa, Ethiopia.
Methods
Ethical approval for this study was obtained from the
Institutional Review Boards of Addis Ababa University
Medical Faculty. The study was conducted without indi-
vidual informed consent because it relied on retrospect-
ive data collected as part of routine patient care. The
study was a hospital-based cohort study at the radiother-
apy centre of Addis Ababa University Hospital. Women
with a histologically verified primary diagnosis of inva-
sive BC between 1 June 2005 and 31 May 2010 who
consulted the radiotherapy department at Tikur Anbessa
Hospital Addis Ababa were included. The files of BC
patients were retrieved manually. All demographic, clinicaland pathological characteristics were documented from
patients’ files containing physicians’ notes, pathology
reports and referral letters.
According to international coding standards for cancer
registries [14], the date of incidence was defined as the
first consultation at a hospital for the cancer in question
or later diagnostic confirmation (e.g. diagnosis by a
physician, pathology, date of death). Information about
tumour size (T) and nodal status (N) was used to derive
the AICC/UICC stage [15]. All staging information men-
tioned within the first three months after primary patho-
logical information was used for TNM staging [16]. In
the case of a clinical T4 description, this was given pri-
ority over any pathological Tx. In case of neoadjuvant
chemotherapy before the operation, clinical T assessed
before chemotherapy was used for the T-stage. TNM
classification recommends the removal of at least six
lymph nodes (LN) of the axilla. This number of 6 LN
was not always described in the pathology report. There-
fore, we decided to classify N1 if >50% of the removed
nodes were positive. In cases of 4–9 or 10+ positive
nodes, we coded N2 or N3. Otherwise, Nx was docu-
mented (in line with the European Network of Cancer
Registries recommendations [17]). M-stage: The pres-
ence of radiologically confirmed distant metastasis at
diagnosis was considered to be M1.
In general, diagnosis of BC was obtained by fine-
needle aspiration cytology (FNAC) or by surgical biopsy.
Early cases were usually operated and therefore tumour
material for histology was available. More advanced,
inoperable cases or recurrences were usually diagnosed
by FNAC only. Therefore, some patients had tumor






Total population n = 1213 352 (100.0) 861 (100.0)
Place of origin
Addis Ababa 183 (52.0) 405 (47.0)
Non-Addis Ababa 140 (39.8) 375 (43.6)
unknown 29 (8.2) 81 (9.4)
Age (years)
<30 56 (15.9) 106 (12.3)
30–39 114 (32.4) 331 (38.4)
40–49 83 (23.6) 231 (26.8)
50–59 53 (15.1) 139 (16.1)
≥60 46 (13.1) 54 (6.3)
Menopausal status
Premenopausal 145 (41.2) 345 (40.1)
Postmenopausal 155 (44.0) 374 (43.4)
Unknown status 52 (14.8) 142 (16.5)
Stage (UICC)
1 and 2 35 (9.0) 153 (17.8)
3 168 (47.7) 288 (33.4)
4 71 (20.2) 72 (8.4)
Unknown 78 (22.2) 348 (40.4)
Distant Metastasis
No (M0) 236 (67.0) 666 (77.4)
Yes (M1) 116 (33.0) 195 (22.6)
Histology
Ductal 265 (75.3) 681 (79.1)
Lobular 20 (5.7) 39 (4.5)
other/unspecified 67 (19.0) 141 (16.4)
Patho-specimen for diagnosis
FNAC+ 127 (36.1) 27 (3.1)
Tumour specimen 193 (54.8) 659 (77.0)
unknown 32 (9.1) 174 (20.2)
Basis of hormone receptor
diagnosis
Primary operation 174 (49.4) Not applicable
Recurrence 106 (30.1)
unknown 72 (20.5)
+FNAC – fine needle aspiration cytology.
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material by FNAC available for ER determination and
grading. Estrogen receptor staining was introduced in a
prospective standardized manner within the independent
Ethiopian BC project separately funded and initiated
by AstraZenaca Ltd., England, facilitated by the Axios
Foundation, France, 2005–2010. Immunohistochemistry
was done soon after the specimen were obtained using
the estrogen antibody ER 6 F11 and progesterone anti-
body PGR 312 with the Menarini detection kit accord-
ing to the standard protocol (A. Menarini diagnostics
International®, Firenze, Italy). Evaluation of the staining
was done by experienced pathologists in the department
according to guidelines assessing any positive stained
cell (>1%) as positive ER status [18].
We estimated the percentage (hereafter referred to as
“prevalence”) of ER status within the total of ER-stained
tumours and among subgroups of clinical importance. To
assess the influence of age on the prevalence of ER-
negative findings, we estimated prevalence ratios (PR) and
corresponding 95% confidence intervals by using a log-
linear regression model. Analyses were done using SAS®
statistical software (SAS Inc., Cary, NC, USA), Version 9.3.
Results
The largest proportion of the study population of 1208
female patients was between 30–39 years old (35%). The
proportion of patients from Addis Ababa (46%) was
slightly higher than the proportion from non-Addis
Ababa; the largest proportion of patients presented at
stage 3 (36%), mostly without distant metastases at diag-
nosis (82%). The majority had ductal histology (78%).
We compared these characteristics between the total
population of 1208 patients and the subgroup of 352
patients with available ER results. The distribution of
place of origin, menopausal status, histology and adju-
vant therapy was similar. Patients with ER results avail-
able were more often under 30 or over 60 years, and
also tended to have a higher stage at diagnosis than
patients with ER results not available. Due to the preferred
procedure of staining FNAC to determine ER, patients
with ER results available had more often FNAC done for
their pathological diagnosis (Table 2).
Within the subgroup of patients with ER results avail-
able, 34.7% (95% CI 28.9–38.8%) had ER-negative
findings. The prevalence of ER-negative findings was
associated with patients age. Based on a log-linear
regression model, the estimated stage-adjusted prevalence
of ER-negative findings decreased for each additional
5 years of age by 6% (PR = 0.94, 95% CI: 0.89–1.00), note
the CI was close to 1.
Progesterone receptor was positive in 72% (162/224) of
ER-positive tumours and 12% (14/120) of ER-negative
tumours. None of the other patient characteristics, includingplace of origin that was not Addis Ababa, stage and
histology, was associated with the prevalence of ER-negative
results (Table 3, adjusted risk ratios). Results from the FNAC
specimen as compared to the tumour specimen had a lower
age- and stage-adjusted prevalence-ratio for ER negativity
(PR = 0.71; 95% CI: 0.51–0.98).
Table 3 ER results among different groups of patients
Parameter ER: N (%) 352 stained tumours
Positive (% in row or
mean and standard
deviation)









Total population n = 352 230 (65.3) 122 (34.7)
Age [years] (mean and standard deviation) 43.0 (13.7) 40.1 (12.6) Increase 5 yrs 1.02
(0.98–1.01)
Increase 5 yrs 0.94
(0.89–1.00)
Tumour size [cm] (mean and standard deviation;
n = 168 results available)
5.47 (3.3) 6.06 (3.3) Increase 1 cm 1.03
(0.98–1.08)
Increase 1 cm 1.03
(0.97–1.08)
Place of origin
Addis Ababa 123 (67.2) 60 (32.8) Reference Reference
Non-Addis Ababa 89 (63.6) 51 (36.4) 1.11 (0.82–1.50) 1.03 (0.76–1.41)
Unknown 18 (62.1) 11 (37.9) 1.16 (0.69–1.93) 1.10 (0.66–1.82)
Menopausal status
Premenopausal 89 (61.4) 56 (38.6) 1.17 (0.87–1.59) 0.81 (0.54–1.23)
Postmenopausal 104 (67.1) 51 (32.9) Reference Reference
unknown 37 (71.2) 15 (28.8) 0.88 (0.54–1.42) 0.62 (0.36–1.07)
Stage (UICC)
1 and 2 24 (68.6) 11 (31.4) 0.89 (0.53–1.52) 0.92 (0.54–1.56)
3 109 (64.9) 59 (35.1) Reference Reference
4 48 (67.6) 23 (32.4) 0.92 (0.62–1.37) 0.96 (0.65–1.42)
Unknown 49 (62.8) 29 (37.2) 1.06 (0.74–1.51) 1.06 (0.75–1.51)
Histology
Ductal 171 (64.5) 94 (35.5) Reference Reference
Lobular 12 (60.0) 8 (40.0) 1.13 (0.64–1.98) 1.05 (0.60–1.85)
Other/unspecified 47 (70.2) 20 (29.8) 0.84 (0.56–1.26) 0.83 (0.56–1.24)
Progesterone receptor
Positive 162 (92.0) 14 (8.0) Reference Reference
Negative 62 (36.9) 106 (63.1) 7.93 (4.74–13.28) 7.81 (4.66–13.09)
Unknown 6 (75.0) 2 (25.0) 3.14 (0.86–11.55) 3.47 (0.94–12.78)
Basis of hormone receptor diagnosis
Primary operation 117 (67.2) 57 (32.8) Reference Reference
Recurrence 62 (58.5) 44 (41.5) 1.12 (0.96–1.31) 1.08 (0.91–1.27)
Unknown basis 51 (70.8) 21 (29.2) 0.89 (0.59–1.35) 0.87 (0.58–1.33)
Patho-specimen for diagnosis
FNAC+ 92 (72.4) 35 (27.6) 0.67 (0.48–0.94) 0.71 (0.51–0.98)
Tumour specimen 114 (59.1) 79 (40.9) Reference Reference
Unknown 24 (75.0) 8 (25.0) 0.61 (0.33–1.14) 0.61 (0.33–1.16)
+FNAC – fine needle aspiration cytology.
*Risk ratios were adjusted for age and stage, unless this was the variable of interest, RR for age was not adjusted.
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In our study, the tumour biology of female Ethiopian BC
patients was favourable: only a small proportion, 34.7%, of
patients had ER-negative BC (results available, n = 352).
Older age predicted lower proportions of ER negativity
(decrease in 5 years: 6.4%). All other patient characteris-
tics, especially advanced stage, histology and ER results
from local recurrence, did not predict ER negativity.Results from FNAC were less often ER-negative than
results from tumour specimens.
Our study is in line with the findings of Jemal et al.
[13], showing that U.S. immigrants from East Africa
have a low proportion of ER-negative breast tumours,
and studies from Nigeria, Ghana, Uganda and from
South Africa that found <35% of ER negativity in BC
patients from Africa [9-12]. The majority of studies on
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negative tumours. Reasons for these findings might be
true differences in the population due to environmental
and genetic factors. However, it cannot be ruled out that
these findings might also reflect bias due to lack of stan-
dardized staining and reading procedures, possible antigen
degradation of archived material, and patient selection.
A limitation of our study is we only tested ER status
on 29% of all the cases. However this group did not dif-
fer much from the total cohort of 1208 cases in clinical
and pathological characteristics. Another limitation of
our study is using results from FNAC staining among
36.1% of the cases instead of the gold standard histologic
staining. In the cohort, FNAC showed a lower propor-
tion of ER-negative results compared to the gold stand-
ard of histologic staining. Even though FNAC is not the
gold standard, we believe FNAC staining does accurately
reflect the immunohistochemical results for the tumour
as comparative studies have shown [19-21]. Since FNAC
is done more often in advanced cancer cases, the group
with available ER results has a higher proportion of
advanced stage patients, i.e. stage 4 (20.2% compared to
8.4%). Additionally, ER was sometimes stained on mater-
ial from local recurrence. Jabbour et al. in their review
article describe a 20% variation of ER expression be-
tween local recurrence and primary tumour, rather than
switching from ER-positive to ER-negative expression in
recurrences. Also, more advanced stages rather tend to
be receptor-negative more frequently [22]. Therefore,
our patient cohort would be expected to have high false
ER-negative expression due to some results originating
from recurrence material compared to the original pri-
mary tumours. Since our findings show a low ER-negative
proportion, this proportion would even be lower in the
primary and early stage tumours often described in studies
from the Western world. Therefore, our results would
even overestimate the proportion of ER-negative findings.
Conclusion
Our study showed that the proportion of ER-negative
BC is low in Ethiopia (35%) using 352 BC cases with
results available from a large consecutive cohort. These
findings are in line with low proportions previously
reported from East-Africa-born US-patients and other
studies from Africa [10,11,13]. In case of low propor-
tions of ER-positive cases in the routine, suspicion
should be raised and a reference laboratory consulted.
Hormone receptor staining is not often available in
Ethiopia due to limited resources. From our findings,
we conclude that patients with unknown receptor sta-
tus are more likely to be ER-positive and therefore
should be treated with Tamoxifen. This is especially
true for older patients with lower chances of ER-
negative disease.Abbreviations
BC: Breast cancer; ER: Estrogen receptor; FNAC: Fine-needle aspiration
cytology; PgR: Progesterone receptor.
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